Saw palmetto fruit extract improves LUTS in type ⅢA prostatitis patients / 中华男科学杂志

Objective@#To assess the clinical efficacy of the saw palmetto fruit extract (SPFE) in the treatment of lower urinary tract symptoms (LUTS) in patients with type ⅢA prostatitis.@*METHODS@#This retrospective study included 54 cases of type ⅢA prostatitis treated in the Outpatient Department of our hospital from January to December 2015. The patients were aged 35.06 ± 5.85 years, with a mean disease course of 3.8 ± 2.1 years, and all received oral medication of SPFE Capsules at the dose of 320 mg qd for 12 weeks. We assessed the therapeutic effects by comparing the NIH-chronic prostatitis symptom indexes (NIH-CPSI), voiding diary, International Prostate Symptom Scores (IPSS), and results of urodynamic examination before and after treatment.@*RESULTS@#Compared with the baseline, both NIH-CPSI and IPSS were significantly decreased after medication (27.61 ± 3.76 vs 18.6 ± 5.34, P <0.01; 20.44 ± 4.51 vs 10.96±4.62, P <0.01), and urodynamic examination and voiding diary showed dramatic post-medication improvement in the average urinary flow rate (［8.05±1.42］ vs ［12.05±2.60］ ml/s, P <0.01 ), maximum urinary flow rate (［14.22±1.74］ vs ［21.32±4.51］ ml/s, P <0.01), residual urine volume (［46.15±16.57］ vs ［14.55±10.21］ ml, P <0.01), maximum urethral closure pressure (［76.52±3.53］ vs ［65.32±4.75］ cm H2O, P <0.01), mean urinary volume (［124.63±40.55］ vs ［285.93±58.68］ ml, P <0.01), urination frequency (16.96±4.17 vs 8.96±2.50, P <0.01), and nocturia frequency (8.94±3.23 vs 3.15±1.90, P <0.01). No apparent adverse reactions were observed in any of the patients.@*CONCLUSIONS@#SPFE Capsules can safely and effectively improve LUTS and thus the quality of life of patients with type ⅢA prostatitis.

[Reproduction of asthma model in ovalbumin-sensitized mice by ovalbumin challenge and lipopolysaccharide induction.].

OBJECTIVE: to reproduce an asthma model in ovalbumin (OVA)-sensitized Balb/C mice by OVA challenge and Lipopolysaccharide (LPS) induction. METHODS: one hundred and twenty BALB/C mice were randomly divided into 6 groups: PBS control group (A group, PBS sensitization and PBS challenge), OVA group (B group, OVA sensitization and OVA challenge), low-dose LPS/LPS group (C1 group, 50 microg LPS sensitization and 50 microg LPS challenge), high-dose LPS/LPS group (C2 group, 100 microg LPS sensitization and 100 microg LPS challenge), low-dose OVA/LPS group (D1 group, OVA sensitization, OVA challenge and 50 microg LPS induction) and high-dose OVA/LPS group (D2 group, OVA sensitization. OVA challenge and 100 microg LPS induction). Asthmatic symptoms were observed. Airway responsiveness were assessed and lung resistance (R(L)) was calculated using a proprietary software program. Cells in bronchoalveolar lavage fluid (BALF) were counted and lung histopathology was evaluated by HE staining. RESULTS: (1) asthma symptoms in either D1 group or D2 group was more severe than other groups, especially in D2 group. (2) The level of total BALF cells, macrophages, lymphocytes, eosinophils, and neutrophils in either D1 group or D2 group was significantly higher than that in A group (P < 0.05, P < 0.01). The level of total BALF cells, lymphocytes, eosinophils, and neutrophils in D1 group was significantly higher than that in B group (P < 0.01, respectively). The level of total BALF cells, macrophages, lymphocytes, and neutrophils in D2 group was significantly higher than those in B group (P < 0.05, respectively). (3) When mice were stimulated by Ach (5.0 g/L), R(L) in either D1 group [(9.32 +/- 1.51) cm H2Oxml(-1)xs(-1) (1 cm H2O = 0.098 kPa)] or D2 group [(44.21 +/- 2.88) cm H2Oxml(-1)xs(-1)] was significantly higher than that in A group [(2.41 +/- 0.35) cm H2Oxml(-1)xs(-1)] and B group [(5.96 +/- 1.83) cm H2Oxml(-1)xs(-1)] (P < 0.01, respectively). (4) More marked and extensive asthma-specific changes in lung was observed in either D1 group or D2 group, especially in D2 group. CONCLUSION: LPS induction in OVA-sensitized Balb/C mice can lead to more severe airway inflammation and greater airway hyperresponsiveness.